Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 39448201 | 2024 | Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models. Journal for immunotherapy of cancer Likely relevant Evaluates the combination of alum-anchored IL-12 (mANK-101) with cisplatin and anti-PD-1, demonstrating enhanced antitumor immune responses including T-cell recruitment and macrophage repolarization in murine models. | mANK-101; cisplatin; alpha-PD-1 | Animal | Head and Neck Squamous Cell Carcinoma | mANK-101 0/0/0; cisplatin 18/3/11; alpha-PD-1 0/0/0 | Awaiting curator check |
| 39461881 | 2024 | Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma. Journal for immunotherapy of cancer Likely relevant The study evaluates anti-PD-1 immunotherapy and an S1P1 inhibitor in murine glioblastoma models, assessing immune phenotypes such as CD8 T cell stemness and cytotoxicity. | anti-programmed cell death protein-1 (PD-1); S1P1 inhibitor | Animal | glioblastoma (GBM) | anti-programmed cell death protein-1 (PD-1) 0/0/0; S1P1 inhibitor 0/0/0 | Awaiting curator check |
| 39475614 | 2024 | Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Science advances Likely relevant The study tests Notch inhibition combined with immune checkpoint blockade in animal models and measures TAM reduction and CTL infiltration. | Notch inhibitors; immune checkpoint blockade (ICB) | Animal | triple-negative breast cancer | Notch inhibitors 0/0/0; immune checkpoint blockade (ICB) 0/0/0 | Awaiting curator check |
| 39488102 | 2024 | Echinacoside inhibits tumor immune evasion by downregulating inducible PD-L1 and reshaping tumor immune landscape in breast and colorectal cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology Likely relevant Tests Echinacoside treatment in mice and cancer cells, showing it downregulates inducible PD-L1, enhances T cell functions, and reshapes the tumor immune landscape. | Echinacoside; anti-PD-1; anti-CTLA-4 | Animal | Breast and Colorectal Cancer | Echinacoside 0/0/0; anti-PD-1 14/36/0; anti-CTLA-4 1/10/7 | Awaiting curator check |
| 39500530 | 2024 | WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. Journal for immunotherapy of cancer Likely relevant Investigates the role of WWOX and pharmacological blockade of SCD5 in combination with anti-PD-1 therapy in humanized orthotopic mouse models and in vitro co-cultures, measuring macrophage and CD8 T cell changes. | anti-PD-1; SCD5 inhibitor | Mixed | hepatocellular carcinoma | anti-PD-1 14/36/0; SCD5 inhibitor 0/0/0 | Awaiting curator check |
| 39515328 | 2024 | Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer cell Likely relevant The study tests CD155 blockade combined with anti-PD-1 therapy in preclinical HCC models and evaluates effects on CD8+ T cell-mediated killing and neutrophil recruitment. | anti-PD-1; anti-PD-L1; CD155 antibody | Animal | hepatocellular carcinoma | anti-PD-1 14/36/0; anti-PD-L1 0/15/0; CD155 antibody 0/0/0 | Awaiting curator check |
| 39561763 | 2024 | Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity Likely relevant Investigates targeting ERAP in combination with ICB in mouse tumor models, measuring CD8+ T cell and NK cell dependence and checkpoint activity. | immune checkpoint blockade (ICB) | Animal | cancer | immune checkpoint blockade (ICB) 0/0/0 | Awaiting curator check |
| 39585102 | 2024 | RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome. Oncoimmunology Likely relevant The study is a short report/summary describing preclinical experiments where a RIPK1 inhibitor improves immunotherapy and radiotherapy outcomes. | RIPK1 inhibitor; PD-1 blockade; CTLA-4 blockade | Animal | unspecified | RIPK1 inhibitor 0/0/0; PD-1 blockade 0/0/0; CTLA-4 blockade 0/0/1 | Awaiting curator check |
| 39629135 | 2024 | SPHK1 promotes HNSCC immune evasion by regulating the MMP1-PD-L1 axis. Theranostics Likely relevant Tests a PD-1 monoclonal antibody in immune-competent mouse models and reports effects on anti-tumor immunity and PD-L1. | PD-1 mAb | Animal | head and neck squamous cell carcinoma | PD-1 mAb 0/1/0 | Awaiting curator check |
| 39641253 | 2024 | Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology Likely relevant The study experimentally tests anti-PD-L1 immunotherapy in combination with microbiota modulation in mouse models and measures immune cell infiltration and cytokine levels. | anti-PD-L1 | Mixed | colorectal cancer | anti-PD-L1 0/15/0 | Awaiting curator check |
| 39657664 | 2024 | Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell reports. Medicine Likely relevant Tests lurbinectedin and PD-L1 blockade in SCLC models and clinical samples, measuring changes in STING signaling, MHC expression, CD8+ T cells, and macrophages. | lurbinectedin; PD-L1 blockade | Mixed | small-cell lung cancer | lurbinectedin 0/0/0; PD-L1 blockade 0/4/0 | Awaiting curator check |
| 39681571 | 2024 | Development of a RIPK1 degrader to enhance antitumor immunity. Nature communications Likely relevant Demonstrates that a novel RIPK1 degrader (LD4172) triggers immunogenic cell death, enhances tumor-infiltrating lymphocytes, and sensitizes tumors to anti-PD1 therapy in mice. | LD4172; anti-PD1 | Animal | Cancer | LD4172 0/0/0; anti-PD1 1/1/0 | Awaiting curator check |
| 39694700 | 2024 | LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. Journal for immunotherapy of cancer Likely relevant The study tests the effects of Skp2 inhibitors (compound #25) and PD-1/PD-L1 blockade immunotherapy in NSCLC cell lines and in vivo models, measuring immune readouts such as TME phenotype and PD-L1 expression. | anti-PD-1; anti-PD-L1; compound #25 | Mixed | non-small cell lung cancer | anti-PD-1 14/36/0; anti-PD-L1 0/15/0; compound #25 0/0/0 | Awaiting curator check |
| 39726591 | 2024 | TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. Frontiers in immunology Likely relevant The study experimentally evaluates the effects of neoadjuvant chemotherapy and immunochemotherapy on immune cell dynamics, TLS density, and T-cell phenotypes in NSCLC patients. | PD-1 inhibitor; chemotherapy | Patient | NSCLC | PD-1 inhibitor 0/0/0; chemotherapy 2/0/3 | Awaiting curator check |
| 35708739 | 2023 | Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients. Cancer immunology, immunotherapy : CII Likely relevant The study experimentally tests immune checkpoint inhibitors on patient-derived T cells and measures effects on immune checkpoints, T cell phenotypes, and cytokine production. | nivolumab; ipilimumab | Patient | oesophageal adenocarcinoma | nivolumab 1/2/4; ipilimumab 1/0/7 | Awaiting curator check |
| 36442849 | 2023 | Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant Uses transgenic mouse models to test targeted macrophage ferroptosis and anti-PD-L1 therapy, measuring macrophage polarization, infiltration, and PD-L1 expression. | anti-PD-L1 therapy; Man@pSiNPs-erastin | Animal | Hepatocellular Carcinoma | anti-PD-L1 therapy 0/0/0; Man@pSiNPs-erastin 0/0/0 | Awaiting curator check |
| 36455783 | 2023 | Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of hepatology Likely relevant Evaluates anti-PD-1 and sorafenib treatment in mouse HCC models and measures immune readouts including tumor-infiltrating CD8+ T cells and chemokine expression. | anti-PD-1; sorafenib | Animal | Hepatocellular Carcinoma | anti-PD-1 14/36/0; sorafenib 27/25/7 | Awaiting curator check |
| 36563773 | 2023 | Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta biomaterialia Likely relevant Examines chemotherapy-induced tumor RNA nanoparticles and their effects on dendritic cell maturation and T cell infiltration in tumour-bearing animals. | chemotherapy | Animal | colon carcinoma | chemotherapy 2/0/3 | Awaiting curator check |
| 36579489 | 2023 | Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. Journal of medicinal chemistry Likely relevant The study tests a novel small-molecule PD-L1 inhibitor (S4-1) in vitro and in vivo and measures its effects on PBMC cytotoxicity toward tumor cells, T-cell activation, and the tumor microenvironment. | S4-1 | Mixed | lung and colorectal cancer | S4-1 0/0/0 | Awaiting curator check |
| 36596787 | 2023 | Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nature communications Likely relevant This is a clinical trial evaluating neoadjuvant chemoimmunotherapy and antiangiogenesis therapy, measuring dynamic changes in the immune microenvironment and T cell receptor repertoires. | camrelizumab; apatinib; S-1; oxaliplatin | Patient | gastric cancer | camrelizumab 0/0/0; apatinib 4/0/0; S-1 2/0/0; oxaliplatin 12/5/2 | Awaiting curator check |
| 36631610 | 2023 | γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature Likely relevant The study investigates the effect of immune checkpoint blockade on gamma delta T cell infiltration and reactivity in MMR-deficient colon cancers with HLA class I defects using patient samples and organoids. | PD-1 blocker; CTLA-4 blocker | Mixed | colon cancer | PD-1 blocker 0/0/0; CTLA-4 blocker 0/0/0 | Awaiting curator check |
| 36649564 | 2023 | Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer discovery Likely relevant The study tests pharmacological and genetic targeting combined with immune-checkpoint blockade in vivo, measuring effects on microglia and CD8+ T cell antigen presentation. | immune-checkpoint blockade; pharmacologic NR4A2 inhibitor | Animal | glioblastoma | immune-checkpoint blockade 0/0/0; pharmacologic NR4A2 inhibitor 0/0/0 | Awaiting curator check |
| 36650022 | 2023 | Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. Journal for immunotherapy of cancer Likely relevant The study experimentally tests statin drugs and anti-PD-1 in murine cancer models and coculture assays, and measures their effects on T-cell killing, activation, and macrophage polarization. | simvastatin; lovastatin; anti-PD-1 | Mixed | head and neck squamous cell carcinoma | simvastatin 0/0/0; lovastatin 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 36669362 | 2023 | Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study investigates regorafenib and ICI therapy and measures their effects on T cell toxicity, Treg infiltration, and cytokine production. | regorafenib; immune checkpoint inhibitor | Mixed | hepatocellular carcinoma | regorafenib 6/3/0; immune checkpoint inhibitor 0/0/0 | Awaiting curator check |
| 36707233 | 2023 | Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut Likely relevant Investigates ferroptosis induction and blockade therapies and their impact on cytotoxic T cell and MDSC infiltration in murine tumour models. | withaferin A; SB225002; alpha-PD-1 | Animal | hepatocellular carcinoma and colorectal cancer | withaferin A 0/0/0; SB225002 0/0/0; alpha-PD-1 0/0/0 | Awaiting curator check |